Page last updated: 2024-11-06

3-methylpiperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-methylpiperidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID79081
CHEMBL ID279512
MeSH IDM0541136

Synonyms (53)

Synonym
BB 0254786
fdi976oyas ,
unii-fdi976oyas
nsc 66494
beta-pipecoline
einecs 210-953-6
beta-methylpiperidine
nsc-66494
piperidine, 3-methyl-
3-pipecoline
3-methylpiperidine
.beta.-pipecoline
nsc66494
.beta.-methylpiperidine
626-56-2
3-methylpiperidine, 99%
CHEMBL279512
3-methyl-piperidine
P0444
AKOS000118976
NCGC00248860-01
dtxcid809195
tox21_200877
dtxsid4029195 ,
NCGC00258431-01
cas-626-56-2
FT-0681582
FT-0616360
AB00557
3-methyl piperidine
(rs) 3-(methyl)piperidine
(+/-)-3-methylpiperidine
racemic 3-methylpiperidine
(3rs)-3-methylpiperidine
racemic 3-methyl-piperidine
AKOS016050407
ss--pipecoline
(rac)-3-methylpiperidine
m-methylpiperidine
j11.560f ,
(rs)-3-methylpiperidine
piperidine, 3-methyl-, (+/-)-
mfcd00005994
F2190-0327
3-methylpiperidine, analytical standard
STL183255
SB18638
SB18636
STR03044
AMY5569
Q27277932
SY273114
EN300-19223
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency53.80033.189029.884159.4836AID1224846
GLI family zinc finger 3Homo sapiens (human)Potency35.15680.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency55.19330.000221.22318,912.5098AID743035; AID743042; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency67.12740.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency75.31820.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency49.39410.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency60.36490.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency53.32120.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency75.31820.000229.305416,493.5996AID1259244; AID1259248
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency60.36490.001024.504861.6448AID743215; AID743227
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency40.41140.023723.228263.5986AID743222; AID743241
activating transcription factor 6Homo sapiens (human)Potency60.36490.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency60.364919.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency42.19830.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency49.43300.039147.5451146.8240AID1224896
heat shock protein beta-1Homo sapiens (human)Potency38.08770.042027.378961.6448AID743210
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency75.31820.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency75.31820.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30518Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -4 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30381Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-51985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.32 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]